Cencora's gross profit for the
three
months ended in Dec. 2023 was $2,469 Mil. Cencora's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was $9,282 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Cencora's gross profit for the
three
months ended in Dec. 2023 was $2,469 Mil. Cencora's Revenue for the
three
months ended in Dec. 2023 was $72,253 Mil. Therefore, Cencora's Gross Margin % for the quarter that ended in Dec. 2023 was 3.42%.
Cencora had a gross margin of 3.42% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage
During the past 13 years, the highestGross Margin % of Cencora was 3.48%. The lowest was 2.49%. And the median was 2.89%.
Cencora Gross Profit Historical Data
The historical data trend for Cencora's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Cencora's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cencora Gross Profit Distribution
For the Medical Distribution industry and Healthcare sector, Cencora's Gross Profit distribution charts can be found below:
* The bar in red indicates where Cencora's Gross Profit falls into.
Cencora Gross Profit Calculation
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Cencora's Gross Profit for the fiscal year that ended in Sep. 2023 is calculated as
Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $9,282 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
Cencora's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Cencora (NYSE:COR) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Cencora had a gross margin of 3.42% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage
Cencora Gross Profit Related Terms
Thank you for viewing the detailed overview of Cencora's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the U.S. pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
COR has been successfully added to your 